Free Trial
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Price, News & Analysis

Genmab A/S logo
$21.69 -0.19 (-0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$21.70 +0.01 (+0.05%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Genmab A/S Stock (NASDAQ:GMAB)

Key Stats

Today's Range
$21.61
$21.83
50-Day Range
$19.08
$23.09
52-Week Range
$17.24
$28.56
Volume
635,193 shs
Average Volume
1.25 million shs
Market Capitalization
$13.92 billion
P/E Ratio
12.32
Dividend Yield
N/A
Price Target
$37.80
Consensus Rating
Moderate Buy

Company Overview

Genmab A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

GMAB MarketRank™: 

Genmab A/S scored higher than 83% of companies evaluated by MarketBeat, and ranked 187th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Genmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Genmab A/S has only been the subject of 1 research reports in the past 90 days.

  • Read more about Genmab A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Genmab A/S are expected to grow by 22.76% in the coming year, from $1.45 to $1.78 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Genmab A/S is 12.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.66.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Genmab A/S is 12.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.11.

  • Price to Earnings Growth Ratio

    Genmab A/S has a PEG Ratio of 6.65. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Genmab A/S has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Genmab A/S's valuation and earnings.
  • Percentage of Shares Shorted

    0.28% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 21.52%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Genmab A/S does not currently pay a dividend.

  • Dividend Growth

    Genmab A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.28% of the float of Genmab A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Genmab A/S has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Genmab A/S has recently decreased by 21.52%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Genmab A/S has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Genmab A/S this week, compared to 6 articles on an average week.
  • Search Interest

    9 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Genmab A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.54% of the stock of Genmab A/S is held by insiders.

  • Percentage Held by Institutions

    Only 7.07% of the stock of Genmab A/S is held by institutions.

  • Read more about Genmab A/S's insider trading history.
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Stock News Headlines

Analysts Offer Predictions for Genmab A/S FY2025 Earnings
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Wall Street Zen Upgrades Genmab A/S (NASDAQ:GMAB) to Buy
Truist Financial Remains a Buy on Genmab (GMAB)
Genmab Announces Changes to its Executive Committee
Completion of Share Buy-back Program
See More Headlines

GMAB Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $20.87 at the beginning of the year. Since then, GMAB shares have increased by 3.9% and is now trading at $21.69.

Genmab A/S Sponsored ADR (NASDAQ:GMAB) released its earnings results on Thursday, May, 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. The firm earned $715 million during the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 35.11% and a trailing twelve-month return on equity of 18.08%.
Read the conference call transcript
.

Genmab A/S (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Genmab A/S's top institutional investors include Eagle Global Advisors LLC (0.03%), Fifth Third Bancorp (0.01%), Truist Financial Corp and Gallacher Capital Management LLC.

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG).

Company Calendar

Last Earnings
5/08/2025
Today
7/21/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMAB
CIK
1434265
Fax
N/A
Employees
2,682
Year Founded
1999

Price Target and Rating

High Price Target
$48.00
Low Price Target
$27.00
Potential Upside/Downside
+74.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.76
Trailing P/E Ratio
12.32
Forward P/E Ratio
14.96
P/E Growth
6.65
Net Income
$1.14 billion
Net Margins
35.11%
Pretax Margin
40.96%
Return on Equity
18.08%
Return on Assets
14.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.34
Quick Ratio
5.32

Sales & Book Value

Annual Sales
$3.12 billion
Price / Sales
4.46
Cash Flow
$1.50 per share
Price / Cash Flow
14.43
Book Value
$8.04 per share
Price / Book
2.70

Miscellaneous

Outstanding Shares
641,540,000
Free Float
631,663,000
Market Cap
$13.92 billion
Optionable
Optionable
Beta
0.94

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:GMAB) was last updated on 7/21/2025 by MarketBeat.com Staff
From Our Partners